Archives
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2018-07
-
vivo vu HMGN proteins are subject to extensive
2024-05-10

HMGN proteins are subject to extensive post-translational modifications which influence both their mode of binding to vivo vu and their functional activity. Like the other HMG protein families, HMGNs are substrates for many of the same enzymes that modify histone proteins (review in [175]). The hist
-
HMGA proteins have also been linked to localized changes in
2024-05-10

HMGA proteins have also been linked to localized changes in chromatin/nucleosome structure and alterations of cellular phenotype during induction of gene transcription in activated T lymphocytes. An adaptive immune response is initiated when naïve resting T lymphocytes encounter their corresponding
-
In addition enhanced AT receptor function abnormally increas
2024-05-10

In addition, enhanced AT1 receptor function abnormally increases central and sympathetic activity, contributing to cardiac and renal disease, which in turn alters homeostasis, increases vulnerability to stress, and further injures the brain, and that AT1 receptor blockade ameliorates excessive sympa
-
br Duality of interest br
2024-05-10

Duality of interest Contribution statement Acknowledgments Introduction Rapid, cell surface-initiated steroid actions have been reported for all major groups of steroid hormones and our understanding of membrane-mediated steroid actions has progressed rapidly over the last two decades. M
-
Our observation that squalestatin caused only small differen
2024-05-10

Our observation that squalestatin caused only small differences in the production of Aβ40 and Aβ42 was in contrast to prior reports of the effects of other cholesterol synthesis inhibitors. This may be due to using squalestatin, a more specific cholesterol synthesis inhibitor that does not affect is
-
Atypically BcALDH has a minor reducing
2024-05-10

Atypically, BcALDH has a minor reducing activity for all-trans-retinal, which requires the binding of the reduced form of the NADP+ (NADPH) cofactor that is a side-product of the canonical oxidation activity of BcALDH. The reduction activity that converts all-trans-retinal to all-trans-retinol was r
-
The only psychostimulant treatment option in Turkey is methy
2024-05-09

The only psychostimulant treatment option in Turkey is methylphenidate (Çetin et al., 2015). It is broken down by carboxylase enzyme (CES1) (Sun et al., 2004). From the point of pharmacokinetics, it may be suggested that CES1 gene polymorphisms may be the key responsible factors in patients resistan
-
Unlike AK inhibition the inhibition of
2024-05-09

Unlike AK inhibition, the inhibition of ADA activities by EHNA had little effect on spinal reflex potentials, although EHNA did increase extracellular adenosine levels. One explanation for this discrepancy is that the adenosine increase seen herein was not sufficient to inhibit reflex potentials. In
-
A review has recently been published to
2024-05-09

A review has recently been published to evaluate the potential effects of food, alcohol and Memantine hydrochloride synthesis juices on the pharmacokinetics and pharmacodynamics of the drugs for BPH. The authors reviewed the PubMed database during the years 1991–2015. In addition, a digital version
-
The gene SRD A encodes
2024-05-09

The gene SRD5A2 encodes the 5-α-reductase enzyme, which converts testosterone into dihydrotestosterone. Although dihydrotestosterone levels are considerably lower than testosterone, dihydrotestosterone has a five-fold stronger binding capacity to the androgen receptor and, thereby, a considerably mo
-
It involves complementary and inflammatory system
2024-05-09

It involves complementary and inflammatory system proteins, mast cells, eosinophils, basophils, macrophages, natural killer (NK) cells and cytokines [1]. Innate immunity, not only include cells, but also barriers that defend the organism to the penetration of pathogenic agents [2]. Important mediat
-
It has been known that LOX is the rate limiting
2024-05-09

It has been known that 5-LOX is the rate-limiting enzyme for the products of LTs, and LTs actively participate in the activation of neutrophils [10]. In our study, we determined whether 5-LOX was upregulated in pancreatic tissues during ANP. Moreover, we investigated whether the inhibition of expres
-
Notably our preliminary results confirmed that fluoxetine SS
2024-05-09

Notably, our preliminary results confirmed that fluoxetine (SSRIs, 5–10 mg/kg) and duloxetine (SNRIs, 5–10 mg/kg) could not enhance memory function in the novel object recognition or step-down passive avoidance tasks (data not shown). In the present study, we also found that vilazodone showed had no
-
Pyrimidine is the important pharmacology core in many
2024-05-09

Pyrimidine is the important pharmacology core in many Aurora inhibitors, such as VX-680, ENMD-2076, CYC-116 and ENMD-2076 [12]. To identify additional effective Aurora inhibitors, we designed a series of 2,4-diaminopyrimidine compounds, our modeling studies suggested that the GSK1363089 core as well
-
Sorafenib Aurora A or B selective
2024-05-09

Aurora -A or -B selective and pan-aurora inhibitors have demonstrated different preclinical and clinical therapeutic efficacies [2,[19], [20], [21], [22], [23]]. For example, clinical trials for a pan-Aurora inhibitor VX-680 (developed by Vertex) were halted at phase II for toxicity reasons (one cas
15077 records 180/1006 page Previous Next First page 上5页 176177178179180 下5页 Last page